ESSA Pharma Inc represents a values-driven and progressive corporate philosophy. With a focus on innovation, integrity, and collaboration, the company strives to advance novel therapies for the treatment of advanced prostate cancer and other hormonally-driven diseases. ESSA Pharma Inc is committed to delivering breakthrough solutions that improve patient outcomes and quality of life. With a dedicated team of experts and a culture of scientific excellence, ESSA Pharma Inc is driven by a strong commitment to addressing unmet medical needs and revolutionizing the field of oncology.

ESSA Pharma Inc is primarily present in the United States and Canada.

ESSA Pharma Inc, a leading pharmaceutical company, has successfully achieved multiple significant milestones. The company made remarkable progress in the development of their product portfolio. Notably, ESSA Pharma Inc received regulatory approvals for several clinical trials, demonstrating their commitment to advancing novel therapies. They also secured strategic partnerships and collaborations with renowned industry players, enabling them to drive further innovation and expand their reach. ESSA Pharma Inc's dedication to researching and developing innovative solutions has positioned them as a key player in the pharmaceutical sector. By focusing on groundbreaking initiatives, they continue to make substantial strides in improving patient outcomes and advancing the field of medicine.

ESSA Pharma Inc. is a biopharmaceutical company specializing in the development of novel medicines for the treatment of prostate cancer. Founded in 2009, ESSA Pharma has made remarkable strides in advancing targeted therapies to improve patients' outcomes. The company focuses on developing drugs that inhibit the N-terminal domain of the androgen receptor, which plays a vital role in the growth and progression of prostate cancer. With a dedicated team of experienced researchers and a robust pipeline, ESSA Pharma Inc. aims to revolutionize prostate cancer treatment by providing innovative and effective therapies to patients worldwide.

The main competitors of ESSA Pharma Inc in the market include leading biotechnology companies such as Genentech, Pfizer, Novartis, and Johnson & Johnson. These companies, like ESSA Pharma Inc, are actively involved in the development and commercialization of innovative pharmaceutical products, including therapeutics for oncology and other diseases. In this competitive landscape, ESSA Pharma Inc aims to differentiate itself by focusing on its unique approach to drug discovery and developing cutting-edge therapies that target therapeutically relevant proteins in cancer.

ESSA Pharma Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of ESSA Pharma Inc revolves around the development and commercialization of novel therapies for the treatment of prostate cancer. As a pharmaceutical company, ESSA Pharma Inc focuses on advancing innovative drugs that target the N-terminal domain of the androgen receptor, a key driver of prostate cancer growth. By leveraging its expertise in drug discovery and clinical development, the company aims to provide effective treatment options for patients suffering from advanced prostate cancer. With a strong emphasis on research and development, ESSA Pharma Inc strives to bring transformative therapies to market, ultimately improving the lives of prostate cancer patients.

Коефициентът на цена спрямо печалбата (КЦП) на ESSA Pharma е -8,57.

Коефициентът на цена към оборот (KUV) на ESSA Pharma е 0.

AlleAktien качественият резултат за ESSA Pharma е 4/10.

Приходите не могат да бъдат изчислени в момента за ESSA Pharma.

очаквана ESSA Pharma печалба е -31,68 млн. USD.

ESSA Pharma Inc. is a Canadian biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. The company focuses on the discovery and development of drugs targeting the androgen receptor (AR) signaling pathway, an important mechanism that contributes to tumor progression in many forms of cancer. The business model of ESSA Pharma Inc. is based on the identification, development, and commercialization of drugs targeting the androgen receptor (AR). The company has focused on the production of new compounds that can inhibit activated androgen receptors. By blocking this protein on the surface of cancer cells, the spread of tumors is expected to be reduced. ESSA Pharma Inc. focuses on the development of pharmaceutical products, with an emphasis on research and development of small molecules that can inhibit the androgen receptor signaling pathway. ESSA is currently in the clinical phase of developing a promising drug called EPI-506. Using an in vitro platform, the company has developed several other molecules that have the potential to be tested in additional clinical trials. The core of ESSA Pharma's business model is the research, development, and commercialization of therapies for the treatment of specific types of cancer, with a focus on prostate cancer. ESSA collaborates closely with experts and researchers in the field of oncology and clinical research to develop the most effective therapies. The company also offers services in the area of clinical trial organization, including support for phase I-II testing, phase III clinical trials, and market strategies. ESSA's services also include the management and operation of clinical trials on behalf of third-party companies. ESSA Pharma's business model is designed for long-term success. By identifying and focusing on a specific target group of cancer patients and collaborating with experienced researchers in the field of oncology and clinical research, the company positions itself as a pioneer and innovator in cancer research. Investments in the research and development of new therapies, as well as the incorporation of expertise in clinical trials and strategies, promote the growth and success of ESSA. Cancer is one of the greatest medical challenges worldwide, and there is a high demand for effective therapies. ESSA Pharma Inc. positions itself as an innovative biopharmaceutical company that is a leader in the treatment of cancer through its research and development of therapies targeting the androgen receptor signaling pathway. With its close collaboration with leading experts in oncology and clinical research, the company is well-positioned to achieve long-term success.

ESSA Pharma разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за ESSA Pharma в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на ESSA Pharma е CA29668H7085.

WKN на ESSA Pharma е A2JKQ4.

Тикерът на ESSA Pharma е EPIX.

През последните 12 месеца ESSA Pharma изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква ESSA Pharma да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на ESSA Pharma в момента е .

ESSA Pharma изплаща дивидент на тримесечие. Той се разпределя в месеците .

ESSA Pharma платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

ESSA Pharma се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от ESSA Pharma на 25.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 25.09.2024 г..

Последното дивидентно плащане беше извършено на 25.09.2024 г..

През година 2023 ESSA Pharma изплати 0 USD под формата на дивиденти.

Дивидентите от ESSA Pharma се изплащат в USD.